Warfarin pharmacogenetics: Up close and personalized

Therapy

Volumn 5, Issue 2, 2008, Pages 125-128

  Carlquist, John F ^a,b   Anderson, Jeffrey L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; WARFARIN;

ALGORITHM; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG TARGETING; EDITORIAL; ENANTIOMER; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; PATIENT CARE; PHARMACOGENETICS; PREDICTION; PROTHROMBIN TIME; RISK REDUCTION; WILD TYPE;

EID: 41949116080     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.2.125     Document Type: Editorial

References (10)

1. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4(1), 39-42 (1994).
2. Furuya H, Fernandez-Salguero P, Gregory W et al.: Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5(6), 389-392 (1995).
3. D'Andrea G, D'Ambrosio RL, di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2), 645-649 (2005).
4. Carlquist JF, Horne BD, Muhlestein JB et al.: Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis 22, 191-197 (2006).
5. Carlquist JF, McKinney JT Nicholas ZP et al.: Rapid melting curve analysis for genetic variants that underlie interindividual variability in stable warfarin dosing. J. Thromb. Thrombolysis (2007) (Epub ahead of print).
6. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007).
7. Caraco Y, Blotnick S, Muszkat M: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. (2007) (Epub ahead of print).
8. Hamberg AK, Dahl ML, Barban M et al.: A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin. Pharmacol. Ther. 81(4), 529-538 (2007).
9. Linder MW, Looney S, Adams JE III et al.: Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J. Thromb. Thrombolysis 14, 227-232 (2002).
10. Millican EA, Lenzini PA, Milligan PE et al.: Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110(5), 1511-1515 (2007).